Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation

被引:151
作者
Hermeling, S
Schellekens, H
Maas, C
Gebbink, MFBG
Crommelin, DIA
Jiskoot, W
机构
[1] Univ Utrecht, UIPS, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands
[2] Univ Utrecht, Cent Lab, Anim Inst, NL-3508 TB Utrecht, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Hematol, Thrombosis & Haemostasis Lab, NL-3508 TB Utrecht, Netherlands
关键词
immunology; interferon alpha2b; protein aggregation; protein structure; proteins; transgenic mice; immune tolerant;
D O I
10.1002/jps.20599
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
The aim of this study was to determine the sensitivity of transgenic immune tolerant mice for the type and level of aggregation of recombinant human interferon alpha2b (rhIFN alpha 2b). RhIFN alpha 2b was aggregated by metal-catalyzed oxidation or by incubation at elevated temperature and various pHs. Native rhIFNa2b was mixed with oxidized rhIFNa2b at different ratios to obtain samples with different aggregation levels. The preparations were characterized by UV and fluorescence spectroscopy, gel permeation chromatography (GPC), dynamic light scattering (DLS), sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting, and ELISA. The immunogenicity was evaluated in wild-type mice and transgenic mice immune tolerant for hIFN alpha 2. Sera were analyzed by ELISA for the presence of rhIFN alpha 2b-specific antibodies. The oxidized and aged preparations widely differed regarding the level and nature of aggregates. All preparations containing aggregates increased the immune response in the wild-type mice as compared to native rhIFNa2b and were able to break the tolerance of the transgenic mice. The more native-like the conformation of the aggregated proteins, the more immunogenic the preparations were in the transgenic mice. The native-like aggregates prepared via metal catalysis induced a dose-dependent loss of tolerance in the transgenic mice. In conclusion, the transgenic mouse model can be used to screen rhIFNa2b formulations for low levels of immunogenic aggregates obtained under accelerated storage conditions. (c) 2006 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 95:1084-1096, 2006
引用
收藏
页码:1084 / 1096
页数:13
相关论文
共 33 条
[1]
Amphlett G, 1996, Pharm Biotechnol, V9, P1
[2]
THE INFLUENCE OF ANTIGEN ORGANIZATION ON B-CELL RESPONSIVENESS [J].
BACHMANN, MF ;
ROHRER, UH ;
KUNDIG, TM ;
BURKI, K ;
HENGARTNER, H ;
ZINKERNAGEL, RM .
SCIENCE, 1993, 262 (5138) :1448-1451
[3]
T helper cell-independent neutralizing B cell response against vesicular stomatitis virus: Role of antigen patterns in B cell induction? [J].
Bachmann, MF ;
Hengartner, H ;
Zinkernagel, RM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (12) :3445-3451
[4]
Purification and conformational properties of a human interferon α2b produced in Escherichia coli [J].
Beldarraín, A ;
Cruz, Y ;
Cruz, O ;
Navarro, M ;
Gil, M .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 2001, 33 (03) :173-182
[5]
Development and use of enzyme-linked immunosorbent assays (ELISA) for the detection of protein aggregates in interferon-alpha (IFN-alpha) formulations [J].
Braun, A ;
Alsenz, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1394-1400
[6]
Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice [J].
Braun, A ;
Kwee, L ;
Labow, MA ;
Alsenz, J .
PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1472-1478
[7]
Determinants of autoantibody induction by conjugated papillomavirus virus-like particles [J].
Chackerian, B ;
Lenz, P ;
Lowy, DR ;
Schiller, JT .
JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6120-6126
[8]
Chackerian B, 2001, J CLIN INVEST, V108, P415, DOI 10.1172/JCI11849
[9]
Physical stability of proteins in aqueous solution: Mechanism and driving forces in nonnative protein aggregation [J].
Chi, EY ;
Krishnan, S ;
Randolph, TW ;
Carpenter, JF .
PHARMACEUTICAL RESEARCH, 2003, 20 (09) :1325-1336
[10]
Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines [J].
Da Silva, DA ;
Schiller, JT ;
Kast, WM .
VACCINE, 2003, 21 (23) :3219-3227